Preview

Научно-практическая ревматология

Расширенный поиск

Лечение IgG4-связанного заболевания

https://doi.org/10.14412/1995-4484-2016-352-360

Полный текст:

Аннотация

IgG4-связанное заболевание (IgG4-СЗ) – это фибровоспалительная патология, характеризующаяся возникновением в различных органах опухолеподобных очагов с уникальной гистологической картиной (муароподобный фиброз, выраженный лимфоплазмоцитарный инфильтрат с большим количеством IgG4+ плазмоцитов, облитерирующий флебит) и повышением уровня IgG4 в сыворотке крови большинства пациентов. Терапией первой линии являются глюкокортикоиды в стартовой дозе 0,6 мг/кг/сут (в пересчете на преднизолон), однако такое лечение сопряжено со множеством неблагоприятных реакций и высоким уровнем рецидивов. В статье приводится обзор имеющейся на сегодняшний день литературы по лечению IgG4-СЗ; особое внимание уделено описанию терапии глюкокортикоидами и ритуксимабом.

Об авторах

Е. В. Сокол
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522 Москва, Каширское шоссе, 34А


В. И. Васильев
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522 Москва, Каширское шоссе, 34А


Список литературы

1. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012 Sep;25(9):1181-92. doi: 10.1038/modpathol.2012.72

2. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012 Feb;22(1):21-30. doi: 10.3109/s10165-011-0571-z

3. Седышев СХ, Васильев ВИ, Ковригина АМ, Насонов ЕЛ. IgG4-связанное системное заболевание. Современный взгляд на «старые» болезни. Научно-практическая ревматология. 2012;50(5):64-72 [Sedyshev SK, Vasiliev VI, Kovriguina AM, Nasonov EL. IgG4-linked systemic disease. modern outlook on «old» disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):64-72 (In Russ.)]. doi: 10.14412/1995-4484-2012-1184

4. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol. 2011 Jan;23(1):67-71. doi: 10.1097/BOR.0b013e328341a240

5. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011 Apr;40(3):352-8. doi: 10.1097/MPA.0b013e3182142fd2

6. Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008 Dec;57(12):1704-12. doi: 10.1136/gut.2008.150979

7. Otsuki M, Chung JB, Okazaki K et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis. J Gastroenterol. 2008;43(6):403-8. doi: 10.1007/s00535-008-2205-6

8. Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria. J Gastroenterol. 2007 May;42 Suppl 18:39-41. doi: 10.1007/s00535-007-2046-8

9. Masaki Y, Shimizu H, Sato Nakamura T, et al. IgG4-related disease: diagnostic methods and therapeutic strategies in Japan. J Clin Exp Hematop. 2014;54(2):95-101. doi: 10.3960/jslrt.54.95

10. Shimizu Y, Yamamoto M, Naishiro Y, et al. Necessity of early intervention for IgG4-related disease – delayed treatment induces fibrosis progression. Rheumatology (Oxford). 2013 Apr;52(4):679-83. doi: 10.1093/rheumatology/kes358

11. Kubota K, Watanaba S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. 2011 Jun;46(6):834-42. doi: 10.1007/s00535-011-0393-y

12. Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014 Jun;49(6):961-70. doi: 10.1007/s00535-014-0945-z

13. Kamisawa T, Okamoto A. Prognosis of autoimmune pancreatitis. J Gastroenterol. 2007 May;42 Suppl 18:59-62. doi: 10.1007/s00535-007-2052-x

14. Ozden I, Dizdaroglu F, Poyanli A, et al. Spontaneous regression of a pancreatic head mass and biliary obstruction due to autoimmune pancreatitis. Pancreatology. 2005;5(2-3):300-3. doi: 10.1159/000085287

15. Miura H, Miyachi Y. IgG4-related retroperitoneal fibrosis and sclerosing cholangitis independent of autoimmune pancreatitis. A recurrent case after a 5-year history of spontaneous remission. JOP. 2009 Jul 6;10(4):432-7.

16. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008 Mar;134(3):706-15. doi: 10.1053/j.gastro.2007.12.009

17. Saeki T, Kawano M, Mizushima I, et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 2013 Oct;84(4):826-33. doi: 10.1038/ki.2013.191

18. Kim HM, Chung MJ, Chung JB. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas. 2010 Jul;39(5):555-60. doi: 10.1097/MPA.0b013e3181c8b4a5

19. Hart PA, Topazian MP, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013 Nov;62(11):1607-15. doi: 10.1136/gutjnl-2012-302886

20. Carruthers MN, Topazian MP, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605

21. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007 Dec;56(12):1719-24. doi: 10.1136/gut.2006.115246

22. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009 Nov;58(11):1504-7. doi: 10.1136/gut.2008.172908

23. Васильев ВИ, Логвиненко ОА, Седышев СХ и др. IgG4-связанное заболевание. Клинические наблюдения. Научно-практическая ревматология. 2013;51(5):578-85 [Vasilyev VI, Logvinenko OA, Sedyshev SKh, et al. IgG4-related disease. Clinical notes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):578-85 (In Russ.)]. doi: 10.14412/1995-4484-2013-1552

24. Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheum. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132

25. Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007 Dec;56(12):1650-2. doi: 10.1136/gut.2007.129833

26. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013 Dec;62(12):1771-6. doi: 10.1136/gutjnl-2012-303617

27. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1089-96. doi: 10.1016/j.cgh.2009.03.021

28. Buechter M, Klein CG, Kloeters C, et al. Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with IgG4- associated cholangitis. Z Gastroenterol. 2014 Jun;52(6):564-8. doi: 10.1055/s-0034-1366331

29. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008 Mar;6(3):364-6. doi: 10.1016/j.cgh.2007.12.020

30. Della-Torre E, Campochiaro C, Bozzolo EP, et al. Methotrexate for maintenance of remission in IgG4-related disease. Rheumatology (Oxford). 2015 Oct; 54(10):1934-6. doi: 10.1093/rheumatology/kev244

31. Khan ML, Colby TV, Viggiano RW, et al. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):217-9. doi: 10.3816/CLML.2010.n.034

32. Miyata KN, Kihira H, Haneda M, et al. IgG4-related tubulointerstitial nephritis associated with membranous nephropathy in two patients: remission after administering a combination of steroid and mizoribine. Case Rep Nephrol. 2014;2014:678538. doi: 10.1155/2014/678538

33. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an openlabel randomised controlled trial. Lancet. 2011 Jul 23;378(9788):338-46. doi: 10.1016/S0140-6736(11)60934-3

34. Tomiyama T, Uchida K, Matsushita M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2011 May;46(5):696-704. doi: 10.1007/s00535-010-0361-y

35. Ko SB, Mizuno N, Yatabe Y, et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology. 2010 May;138(5):1988-96. doi: 10.1053/j.gastro.2010.01.001

36. Hirano K, Shiratori Y, Komatsu Y, et al. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol. 2003 Nov;1(6):453-64. doi: 10.1016/S1542-3565(03)00221-0

37. Kanno A, Masamune A, Okazaki K, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas. 2015 May;44(4):535-9. doi: 10.1097/MPA.0000000000000325

38. Hirano K, Tada M, Isayama H, et al. Indication for steroid therapy in autoimmune pancreatitis patients without obstructive jaundice. Abstract. 2nd International symposium on IgG4-RD and associated conditions. 2014.

39. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1010-6. doi: 10.1016/j.cgh.2006.05.017

40. Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2014 Apr;49(4):567-88. doi: 10.1007/s00535-014-0942-2

41. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993 Dec 15;119(12):1198-208. doi: 10.7326/0003-4819-119-12-199312150-00007

42. Matsushita M, Yamashina M, Ikeura T, et al. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am J Gastroenterol. 2007;102:220-1.

43. Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond's disease: «idiopathic» retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore). 2013 Mar;92(2):82-91. doi: 10.1097/MD.0b013e318289610f

44. Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas. 2003 Oct;27(3):235-8. doi: 10.1097/00006676-200310000-00007

45. Nishimori I, Tamakoshi A, Kawa S, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006 Apr;32(3):244-8. doi: 10.1097/01.mpa.0000202950.02988.07

46. Uchida K, Yazumi S, Nishio A, et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol. 2009;44(7):726-32. doi: 10.1007/s00535-009-0049-3

47. Kamisawa T, Egawa N, Nakajima H, et al. Extrapancreatic lesions in autoimmune pancreatitis. J Clin Gastroenterol. 2005 Nov-Dec;39(10):904-7. doi: 10.1097/01.mcg.0000180629.77066.6c

48. Wu A, Andrew NH, Tsirbas A, et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond). 2015 Jan;29(1):122-8. doi: 10.1038/eye.2014.251

49. Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010 Jun;62(6):1755-62. doi: 10.1002/art.27435

50. Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. 344 с. [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Moscow: IMA-PRESS; 2012. 344 p.].

51. Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008 Dec;128(12):2745-7. doi: 10.1038/jid.2008.330

52. Murakami J, Matsui S, Ishizawa S, et al. Recurrence of IgG4-related disease following treatment with rituximab. Mod Rheumatol. 2013 Nov;23(6):1226-30. doi: 10.3109/s10165-012-0738-2

53. Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. Ann Rheum Dis. 2015 Aug;74(8):e46. doi: 10.1136/annrheumdis-2015-207625

54. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012 Jan;91(1):57-66. doi: 10.1097/MD.0b013e3182431ef6

55. Васильев ВИ, Пальшина СГ, Симонова МВ и др. Первый опыт использования ритуксимаба в терапии болезни Микулича. Терапевтический архив. 2010;82(6):62-6 [Vasil’ev VI, Pal’shina SG, Simonova MV, et al. The first experience with rituximab in the treatment of Mikulic’s disease. Terapevticheskii Arkhiv. 2010;82(6):62-6 (In Russ.)].

56. Grimm KE, Bakke A, O'Malley DP. Abnormal expression of CD20 on IgG4 plasma cells associated with IgG4-related lymphadenopathy. Arch Pathol Lab Med. 2013 Sep;137(9):1282-5. doi: 10.5858/arpa.2012-0466-OA

57. Della-Torre E, Feeney E, Deshpande V, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis. 2015 Dec;74(12):2236-43. doi: 10.1136/annrheumdis-2014-205799

58. Седышев СХ, Васильев ВИ, Ковригина АМ и др. Заболевание, связанное с IgG4: характеристика группы больных и терапия ритуксимабом. Терапевтический архив. 2013;85(2):48-53 [Sedyshev SKh, Vasil'ev VI, Kovrigina AM, et al. The disease is associated with IgG4: the characteristic group of patients and rituximab therapy. Terapevticheskii arkhiv. 2013;85(2):48-53 (In Russ.)].


Для цитирования:


Сокол Е.В., Васильев В.И. Лечение IgG4-связанного заболевания. Научно-практическая ревматология. 2016;54(3):352-360. https://doi.org/10.14412/1995-4484-2016-352-360

For citation:


Sokol E.V., Vasilyev V.I. TREATMENT OF IgG4-RELATED DISEASE. Rheumatology Science and Practice. 2016;54(3):352-360. (In Russ.) https://doi.org/10.14412/1995-4484-2016-352-360

Просмотров: 799


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)